Psy Therapeutics Set to Showcase Innovations at Virtual Life Science Investor Forum on March 13, 2025

Psy Therapeutics, a promising Boston-based biopharmaceutical company, is gearing up to present groundbreaking advancements in the treatment of neuropsychiatric and neurodegenerative disorders at the upcoming Virtual Life Science Investor Forum. Scheduled for March 13, 2025, at 11:00 AM EDT, the live-streamed event will feature David Barlow, the Chair & CEO, alongside Alan Cross, the Chief Scientific Officer. Investors will have the unique opportunity to engage with the company's leaders during a real-time Q&A session, diving deeper into their innovative research and development initiatives.

For those unable to attend the live event, a recorded version will be accessible afterward to ensure that all interested investors can stay informed. Participants are encouraged to pre-register in advance and conduct system checks to enhance their experience during the forum.

Recent Breakthroughs and Future Directions

Psy Therapeutics is creating a name for itself with its impressive pipeline of drug candidates:

- **PSY-05**: This oral medication is poised to become a first-in-class treatment for both subacute and chronic pain, as well as post-traumatic stress disorder (PTSD). Recent studies demonstrated significant efficacy in preclinical pain models, with IND-enabling research currently underway. The compound has received a critical patent allowance in the US, securing its protection until at least 2042.

- **PSY-01**: This oral treatment aims to be a game-changer for Parkinson’s Disease and presents a potential breakthrough therapy for depression. The program is advancing rapidly through lead optimization, with important biomarker data expected to be released in March, supported by funding from the National Institute of Mental Health.

- **PSY-02**: Targeting neurodegenerative diseases, this program focuses on inhibiting Tau oligomerization. Preliminary results have confirmed the Tau anti-aggregation properties of the compound in cell-based studies, with further findings anticipated in the second half of 2025, thanks to financial backing from the Michael J. Fox Foundation.

About Psy Therapeutics

Psy Therapeutics is on a mission to develop innovative medicines that can transform the lives of those battling neuropsychiatric and neurodegenerative disorders. Utilizing cutting-edge chemistry-driven technologies, the company is committed to creating effective therapies that address the limitations of current treatments. With a leadership team brimming with expertise, coupled with insights from a distinguished Scientific Advisory Board, Psy Therapeutics is poised for significant breakthroughs in the healthcare landscape.

Don't Miss Out!

Register now for the Virtual Life Science Investor Forum and be part of a transformational moment in medical innovation. For more information, visit [Psy Therapeutics' website](https://psythx.com).

Stay Ahead of the Curve

This presentation could unveil the next big development in neuropharmaceuticals. Mark your calendars for March 13, and join the conversation on how Psy Therapeutics is changing the future of healthcare!